Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit

August 7, 2025 Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases

French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …
News
lungs

M42 study highlights positive performance of AI model for tuberculosis screening

August 6, 2025 Research and Development AI, Infections and infestations, M42, X-ray, tuberculosis

Healthcare tech company, M42, has published results from one of the largest real-world studies of an artificial intelligence (AI)-powered tuberculosis …
News
brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

August 6, 2025 Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …
News
blood-1813410_960_720

FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate

August 6, 2025 Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …
News

Freya Pharma launches phase 2 study of therapy for female sexual dysfunction

August 5, 2025 Research and Development Female Sexual Interest/Arousal Disorder (FSIAD), Freya Pharma Solutions, Genito-Urinary system, sexual health

Freya Pharma Solutions has announced the initiation of a phase 2 study evaluating its Lybrido to treat female sexual interest/arousal …
News

Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy

August 4, 2025 Research and Development Duchenne Muscular Dystophy, Hansa Biopharma, Rare Diseases, Sarepta Therapeutics, clinical trial, genetic disorder

Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the use of imlifidase as a …
News

A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK

August 3, 2025 Research and Development Crohn’s disease, Immunology, Lilly UK, autoimmune disease, immunology

By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in the UK is at a …
Feature

Ryvu Therapeutics publishes research revealing potential drug combination for colorectal cancer

August 1, 2025 Medical Communications, Research and Development Oncology, Ryvu Therapeutics, colorectal cancer

Ryvu Therapeutics has published new findings from its ONCO Prime target discovery platform in Scientific Reports. The study reveals a …
News

Richmond Pharmacology appoints Priscilla Ochuba as associate medical director

August 1, 2025 Research and Development Contract Research Organsation, Corporate, Pharmacy, Richmond Pharmacology, associate medical director

Richmond Pharmacology has announced the promotion of Priscilla Ochuba to associate medical director, effective 1 August 2025. The move recognises …
Appointment

Labguru and Titian Software rebrand as Cenevo to accelerate connected labs

July 31, 2025 Analytical & Laboratory Services, Research and Development Cenevo, Corporate, Labguru, Laboratory management

Lab management companies, Labguru and Titian Software, have rebranded under a new unified name, Cenevo. This combines their solutions, Mosaic …
News
lab

Hansa Biopharma bolsters leadership team with new executive appointments

July 31, 2025 Research and Development Chief Human Resources Officer, Chief Legal Officer, Corporate, Executive Leadership Team, Hansa Biopharma, Vice President Corporate Affairs

Hansa Biopharma has announced three senior leadership appointments to support its global expansion as well as pre-commercial activities in the …
Appointment

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

July 30, 2025 Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …
News
laboratory-testing-az

Clinisys acquires Orchard Software to expand laboratory informatics leadership

July 30, 2025 Analytical & Laboratory Services, Mergers and Acquisitions, Research and Development Clinisys, Corporate, Francisco Partners, Orchard Software, laboratory informatics, laboratory information management systems

Clinisys has announced the acquisition of Orchard Software from Francisco Partners, strengthening its position in laboratory informatics. The strategic acquisition …
News
alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

July 30, 2025 Research and Development Alzheimer's disease, CE Mark approval, Eli Lilly, Neurology, Roche

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in vitro diagnostic regulation-certified blood-based diagnostic …
News
europe-1395916_640

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment

July 30, 2025 Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026